BIO-ENGINEERED STENT MARKET ANALYSIS

Bio-engineered Stent Market, by Application Type (Coronary Artery Disease, Peripheral Arterial Disease, Carotid Artery Disease, Renal Artery Stenosis, Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Others), by Product Type (Drug-eluting Stents, Bioabsorbable Stents, and Drug-eluting Balloons), by Mode of Delivery (Balloon-expandable Stents and Self-expanding Stents), by Material Type (Metal-based and Polymer-based), by End User (Hospitals & Cardiac Centers and Ambulatory Surgical Centers, Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Industry Insights and Forecast to 2026

Published In : Feb 2019
Code : CMI2484
Pages :176
Formats :
Excel and PDF
Industry : Medical Devices

Bio-engineered Stent MarketSize and Trends

The global bio-engineered stent market size was valued at US$ 2,764.2 million in 2017, and is projected to exhibit a CAGR of 8.7% over the forecast period (2018 – 2026).

Bio-engineered stent is used in treating blockage of coronary and peripheral artery, which is related to coronary heart disease, ischemic heart disease, and other cardiovascular diseases. High prevalence of coronary heart disease, ischemic heart disease, and other cardiovascular diseases is expected to propel demand for bio-engineered stent, which in turn is expected to drive the market growth. According to American Heart Association, in 2018, around 92.1 million people in the U.S. were suffering with some form of cardiovascular diseases or the after-effects of stroke. Moreover, around 836,546 deaths in the U.S. were due to cardiovascular diseases, which accounted for 1 in every 3 deaths in the country. Direct and indirect costs in the treatment of cardiovascular diseases and stroke in the country were estimated to be around US$ 329.7 Million in 2018, which includes both health expenditures and lost productivity.

Similarly, according to World Health Organization (WHO), 2015, cardiovascular diseases are the highest cause of morbidity and mortality worldwide, with around 17.7 million cases representing 31% of all worldwide deaths in 2015, of which around 6.7 million were due to stroke and 7.4 million were due to coronary heart disease.

Increasing adoption of bio-engineered stents in North America is expected to bolster the market growth

Bio-engineered Stent Market Report Snapshots